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A B S T R A C T
Background
Intravenous albumin infusion to treat hypoalbuminaemia is used in intensive care nurseries. Hypoalbuminaemia occurs in a number of
clinical situations including prematurity, the acutely unwell infant, respiratory distress syndrome (RDS), chronic lung disease (CLD),
necrotising enterocolitis (NEC), intracranial haemorrhage, hydrops fetalis and oedema. Fluid overload is a potential side effect of
albumin administration. Albumin is a blood product and therefore carries the potential risk of infection and adverse reactions. Albumin
is also a scarce and expensive resource.
Objectives
The primary objective was to assess whether albumin infusions, in preterm neonates with low serum albumin, reduces mortality and
morbidity. A secondary objective was to assess whether albumin infusion is associated with significant side effects.
Search strategy
Searches were made of MEDLINE from 1966 to April 2004, CINAHL from 1982 to April 2004 and the current Cochrane Central
Register of Controlled Trials (CENTRAL, The Cochrane Library issue 1, 2004). Previous reviews (including cross references) and
abstracts were also searched.
Selection criteria
All randomised controlled trials in which individual patients were allocated to albumin infusion versus control were included. Cross-
over studies were excluded. Quasi randomised trials were excluded. Participants were preterm infants who had hypoalbuminaemia.
Types of interventions included albumin infusion versus placebo (e.g. crystalloid) or no treatment.
Data collection and analysis
The reviewers worked independently to search for trials for inclusion and to assess methodological quality. Studies were assessed using
the following key criteria: blinding of randomisation, blinding of intervention, completeness of follow up and blinding of outcome
measurement.
Main results
Only two small studies were found for inclusion in this review and only one reported clinically relevant outcomes - it found no
significant differences for our primary outcome measure of death (RR 1.5 [95% confidence interval 0.3 - 7.43]) or secondary outcome
measures of intraventricular haemorrhage, patent ductus arteriosus, necrotising enterocolitis, bronchopulmonary dysplasia, duration
of mechanical ventilation and duration of oxygen therapy.
Authors’ conclusions
There is a lack of evidence from randomised trials to determine whether the routine use of albumin infusion, in preterm neonates with
low serum albumin, reduces mortality or morbidity, and no evidence to assess whether albumin infusion is associated with significant
side effects. There is a need for good quality, double-blind randomised controlled trials to assess the safety and efficacy of albumin
infusions in preterm neonates with low serum albumin.
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P L A I N L A N G U A G E S U M M A R Y
There is a lack of evidence from randomised trials to either support or refute the routine use of albumin infusion for premature babies
with a low albumin level.
Albumin is a substance that is normally present in the blood. In premature babies the albumin level in the blood can be low. Albumin is
often given to premature babies with a low albumin level. Only two small randomised controlled trials have studied the use of albumin
in sick premature babies, and the trials are not big enough or good enough to decide whether giving albumin helps babies in the short
or long term. We, therefore, cannot answer the question of whether giving albumin does any good and is safe.
B A C K G R O U N D
Serum albumin levels are routinely measured and reported in in-
tensive care nurseries and hypoalbuminaemia is a common find-
ing in preterm (<37 weeks) neonates (<28 days). An older child or
adult with a serum albumin level below 30 g/litre is classified as
having hypoalbuminaemia (Greenough 1998). Normal albumin
levels in preterm infants have been difficult to define. Serum al-
bumin levels in preterm infants are significantly lower than those
in term infants (Bergstrand 1972; Cartlidge 1986; Zlotkin 1987;
Reading 1990). Cartlidge and Rutter (Cartlidge 1986) showed
serum albumin levels in the early neonatal period increased signif-
icantly with gestational age from a mean of 19 g/litre (90% confi-
dence interval ~12 to ~28 g/litre) below 30 weeks to a mean of 31
g/litre (90% confidence interval ~22 to ~39 g/litre) at term. Hy-
poalbuminaemia occurs in a number of clinical situations includ-
ing prematurity, the acutely unwell infant, respiratory distress syn-
drome (RDS), chronic lung disease (CLD), necrotising enterocol-
itis (NEC), intracranial haemorrhage, hydrops fetalis and oedema
(Green 1993; Greenough 1999; Atkinson 1989; Bergstrand 1972;
Cartlidge 1986; Zlotkin 1987; Reading 1990).
There are several clearly defined physiological functions of serum
albumin. These include a binding and transport function, an ef-
fect on colloid osmotic pressure with serum albumin accounting
for approximately 60-80% of the colloid osmotic pressure, a role
as a free radical scavenger and anticoagulant effects primarily in
inhibiting platelet aggregation and increasing prothrombin and
partial prothrombin time (Margarson 1998). Albumin accounts
for approximately 50% of the serum proteins and is the major
protein produced by the liver (Vanek 1998).
In acute and chronic lung disease of the newborn, alveolar capil-
lary membrane permeability is increased and high albumin levels
are present in the alveolar aspirate (Watts 1995). In conjunction
with this, pulmonary oedema is often found. Protein leakage into
the alveolar space has been shown to occur in adults with respira-
tory distress syndrome. Leakage of protein into the alveolar space
interferes with lung function and inactivates surfactant (Moison
1998). It has been suggested that albumin infusions should in-
crease the capillary colloid pressure, thereby resulting in a decrease
in flow of fluid out of the capillaries. This should then lessen fluid
accumulation in the lungs, bowel wall and other interstitial spaces
that could cause decreased pulmonary oxygen uptake, decreased
absorption across the bowel wall or increased bowel wall secretions
(Vanek 1998). However, it could also be argued that the underly-
ing capillary leak will not be altered by albumin infusion and that
increasing the amount of intravascular albumin will increase the
amount that leaks out of the circulation, into the tissues, increas-
ing oedema.
Low albumin levels have been found in infants who develop necro-
tising enterocolitis (Atkinson 1989). Albumin contributes to the
antioxidant capacity of plasma; therefore, low levels of plasma al-
bumin may lessen the total plasma antioxidant capacity. This may
be of importance for preterm infants who are at risk of disease pro-
cesses where reactive oxygen species are believed to play an impor-
tant role such as respiratory distress syndrome, chronic neonatal
lung disease and intracranial haemorrhage (Moison 1998).
Hypoalbuminaemia in adult surgical and medical patients has
been associated with an increased incidence of pneumonia, septi-
caemia, mortality and longer hospital stay (Vanek 1998). Gold-
wasser and Feldman (Goldwasser 1997) showed that in adults,
serum albumin concentration is inversely related to the risk of
death. Conversely a systematic review of albumin administration
in critically ill adults found no evidence that albumin administra-
tion reduced mortality and suggested that it may increase mortal-
ity in selected patients (Cochrane 1998). Studies in adults have
looked at the influence of albumin on duration of intensive care
stay and rate of recovery. Stockwell et al (Stockwell 1992) showed
no difference between duration of stay, complications or outcomes
in two groups of patients who had either albumin or gelatin for
fluid replacement.
There are documented cases of the complete absence of albumin,
analbuminaemia, as a result of a rare genetic condition (Watkins
1994). These patients suffered only mild abnormalities of lipid
metabolism and mild oedema; half of the reported patients were
entirely asymptomatic. Several studies have shown that oedema in
preterm infants is common but poorly correlated with hypoalbu-
minaemia (Cartlidge 1986; Reading 1990; Kenny 1995) and the
routine administration of albumin for oedema is not warranted.
Intravenous albumin infusion to treat hypoalbuminaemia is used
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in intensive care nurseries. Green and Morgan (Green 1993) sug-
gested giving 20% albumin whenever the serum albumin falls be-
low 25 g/litre. Intravenous albumin has also been administered to
high risk infants who are hypotensive and in respiratory distress
(Lay 1980). It has been advocated in the past that ill infants with
RDS should be given albumin infusions whenever their serum al-
bumin falls below 20 g/litre (Greenough 1992); however, it is now
recommended that care should be taken as albumin infusions may
be harmful (Greenough 1999).
Using albumin to treat hypoalbuminaemia is different from using
albumin for volume expansion which has been assessed in other
Cochrane reviews (Alderson 2002; Bunn 2002; Osborn 2002).
Fluid overload is a potential side effect of albumin administra-
tion. Complications of fluid overload include PDA and NEC and
possibly CLD (Greenough 1999). Albumin is a blood product
and therefore carries the potential risk of infection and adverse
reactions; although the risks are low, they should be considered.
Albumin (which comes in a number of commercial preparations
with concentrations ranging from 4 - 20%) is also a scarce and ex-
pensive resource with hospitals frequently experiencing shortages
(Golub 1994).
O B J E C T I V E S
The primary objective was to assess whether albumin infusions, in
preterm neonates with low serum albumin, reduces mortality and
morbidity. A secondary objective was to assess whether albumin
infusion is associated with significant side effects.
Data permitting, sub-group analyses were planned to determine
whether results differed by:
Population:
i. gestational age (e.g. extremely premature [less than or equal to
28 weeks] versus premature [29 to 36 weeks]).
ii. birthweight (e.g. very low birth weight infants, <1500 grams,
versus infants greater than or equal to 1500 grams or extremely
low birth weight infants [<1000 grams] versus infants greater than
or equal to 1000 grams).
iii. infants with particular illnesses or signs (e.g. oedema, RDS,
CLD)
iv. hypoalbuminaemia (e.g. less than 30 g/L or less than 25 g/L or
less than 20 g/L)
Intervention:
i. dose of albumin infused (e.g. < 1.5 g/kg/dose versus greater than
or equal to 1.5 g/kg/dose)
ii. type of treatment used in the control group (placebo [e.g. crys-
talloid] or no treatment)
iii. whether albumin is a single infusion on one occasion or a policy
of repeated infusions to maintain a serum albumin above a certain
level
C R I T E R I A F O R C O N S I D E R I N G
S T U D I E S F O R T H I S R E V I E W
Types of studies
All randomised controlled trials in which individual patients were
allocated to albumin infusion versus control. Cross-over studies
were excluded. Quasi randomised trials were excluded.
Types of participants
Preterm infants who had hypoalbuminaemia. Hypoalbuminaemia
defined as < 30 g/L, <25 g/L and < 20 g/L.
Types of intervention
Albumin infusion versus placebo (i.e. any other non-colloidal fluid
that does not contain albumin) or no treatment. Albumin infusion
included any regimen from a single infusion on one occasion to a
policy of repeated infusions to maintain the serum albumin above
a certain level.
Types of outcome measures
Primary outcomes:
Mortality (neonatal [28 days], before discharge)
Neurodevelopmental outcome at 1 year, 18 months, 2 years, 5
years
Secondary outcomes:
Chronic lung disease (requiring oxygen at 28 days or 36 weeks
post-menstrual age)
Intraventricular haemorrhage (any, grade 3-4)
Duration of mechanical ventilation (IPPV) - hours/days
Duration of respiratory support (IPPV or CPAP) - hours/days
Duration of oxygen therapy - hours/days
Septicaemia
Necrotising enterocolitis
Duration of ICN stay - hours/days
Duration of hospital stay - hours/days
Patent ductus arteriosus requiring therapy (medical or surgical)
Cost
Immediate adverse effects (e.g. hypertension, increased ventilation
requirements and increased oxygenation)
S E A R C H M E T H O D S F O R
I D E N T I F I C A T I O N O F S T U D I E S
See: Neonatal Group methods used in reviews.
The standard search strategy for the Cochrane Neonatal Review
Group was used: Searches were made of MEDLINE from 1966 to
April 2004, CINAHL from 1982 to April 2004 and the current
Cochrane Central Register of Controlled Trials (CENTRAL, The
Cochrane Library Issue 1, 2004), using the following strategy:
MeSH search terms ’serum albumin’, OR ’albumins’; OR the
text words ’albumin’, OR ’albumen’, OR ’hypoalbuminemia’, OR
3Albumin infusion for low serum albumin in preterm newborn infants (Review)
Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd
’hypoalbuminaemia’, OR ’hypo-albuminemia’, OR ’hypo-albu-
minaemia’;
AND
MeSH search term ’infant, newborn’
AND
MeSH terms ’*Albumins / ad [Administration & Dosage]’, OR
’Albumins / tu [Therapeutic Use]’, OR ’*Albumins / pd [Pharma-
cology]’, OR the text word phrase “albumin infusion”
Previous reviews (including cross references), and abstracts were
also searched. Searches were not restricted to publications in the
English language or published data.
M E T H O D S O F T H E R E V I E W
Criteria and methods used to assess the methodological quality of
the trials:
Standard methods of the Cochrane Collaboration (Clarke 2002)
and its Neonatal Review Group were used. The reviewers worked
independently to search for trials for inclusion and to assess
methodological quality. Studies were assessed using the following
key criteria: blinding of randomisation, blinding of intervention,
completeness of follow up and blinding of outcome measurement.
However, quality criteria did not determine whether a study was
excluded or included from this review. Data were extracted inde-
pendently by the reviewers. Differences were resolved by discus-
sion and consensus of the reviewers. Investigators were contacted
for additional information and data where necessary.
For individual trials, where possible, mean differences (and 95%
confidence intervals) were reported for continuous variables. For
categorical outcomes, the relative risk and risk difference (and 95%
confidence intervals) were reported.
For the meta-analysis, where possible, weighted mean differences
(and 95% confidence intervals) were planned to be reported for
continuous variables, and the relative risk and risk difference (and
95% confidence intervals) for categorical outcomes. A fixed effects
model was planned. Number needed to treat was to be calculated
where appropriate.
Given sufficient numbers of included studies we planned to test
for heterogeneity where appropriate before deciding to pool the
results.
D E S C R I P T I O N O F S T U D I E S
The above search strategy found only three possibly eligible studies
of albumin infusions in hypoalbuminaemic preterm infants: two
are included in this review.
Kanarek et al (Kanarek 1992) studied the concurrent adminis-
tration of albumin versus placebo with total parenteral nutrition
(TPN) in 24 premature infants (12 in each group). To be eligible
the infants had to (1) have respiratory distress requiring assisted
ventilation; (2) have had significant hypotension (2 SD below the
mean for gestational age, necessitating the use of a plasma expander
and/or inotropic agents); (3) have a plasma albumin level below
30 g/L at 48 to 72 hours of life and (4) require TPN for nutri-
tional support. Therefore the population studied in this study was
a subset of the population of interest for this review. The albumin
was added to the TPN in quantities that were calculated to raise
the serum albumin above 30 g/L (maximum 1 g/kg/day).
Greenough et al (Greenough 1993) studied the effect of albumin
infusion versus placebo on 40 premature infants (28 - 34 weeks
gestational age, 20 in each group). Study subjects were newborn
infants who were ventilator dependant at less than seven days of
age and had a serum albumin level of ≤30 g/L. Therefore the
population studied in this study was once again a subset of the
population of interest for this review. Infants were not eligible if
they were receiving peritoneal dialysis, had chest drains in situ or
were hypotensive (defined as systolic blood pressure less than 40
mmHg). Infants were randomised (the method of randomisation
is unknown) to receive either albumin administered as 5 ml/kg of
20% salt-poor human albumin or placebo (5 ml/kg of the infants
maintenance fluids). Attempts were made to contact the primary
author and no reply was received (we requested clarification of
blinding of randomisation, blinding of intervention, completeness
of follow up and blinding of outcome measurement; and whether
other data were available for any of our primary and secondary
outcomes).
The study by Bland et al (Bland 1973) investigated albumin in-
fusions in low birth weight newborn infants at risk for respiratory
distress who were acidaemic with a low total serum protein level
(whether they were hypoalbuminaemic or not is unknown).
M E T H O D O L O G I C A L Q U A L I T Y
Kanarek et al (Kanarek 1992):
• blinding of randomisation (allocation concealment) - yes
• blinding of intervention - yes
• completeness of follow up - yes
• blinding of outcome measurement - unknown
Greenough et al (Greenough 1993):
• blinding of randomisation (allocation concealment) - unknown
• blinding of intervention - unknown
• completeness of follow up - no (data were analysed and reported
for only 15 out of 20 subjects in each group)
• blinding of outcome measurement - unknown
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R E S U L T S
We report the results of individual studies. Due to the significant
heterogeneity in study quality and the lack of pre-specified out-
comes in one of the studies we have not attempted to pool the
results.
The results below are organised using our pre-specified primary
and secondary outcomes.
Kanarek et al (Kanarek 1992)
This study found no significant effect of albumin infusion on any
of our pre-specified primary and secondary outcomes.
Primary outcome measures:
• Mortality - there were 3/12 deaths in the experimental group
and 2/12 deaths in the control group: RR 1.5 (95% confidence
interval 0.3 to 7.43). It is not stated whether mortality is 28 day
mortality or at discharge
• Neurodevelopmental outcomes were not assessed or reported
Secondary outcomes:
• There were 5/12 intraventricular haemorrhages (not further de-
fined) in the experimental group and 4/12 in the control group:
RR 1.25 (95% confidence interval 0.44 to 3.55)
• There was 0/12 infants with necrotising enterocolitis in the
experimental group and 1/12 in the control group: RR 0.33
(95% confidence interval 0.01 to 7.45)
• 5/12 patients in the experimental group and 6/12 in the control
group had bronchopulmonary dysplasia (not further defined):
RR 0.83 (95% confidence interval 0.35 to 2.0)
• 5/12 patients in the experimental group and 7/12 in the control
group had a patent ductus arteriosus (not further defined): RR
0.71 (95% confidence interval 0.31 to 1.63)
• The mean duration of assisted ventilation in the experimental
group was 36.9 days (SD 22.9), the mean duration in the control
group was 30.8 days (SD 15.2). Mean difference 6.1 days (95%
confidence interval -9.45 to 21.65)
• The mean duration of oxygen therapy in the experimental group
was 45.7 days (SD 19.1), the mean duration in the control
group was 40.4 days (SD 12.5). Mean difference 5.3 days (95%
confidence interval -7.62 to 18.22)
The mean arterial blood pressures (MABP) were reported for days
three and six. There was no significant differences between the
two groups in the first few days of life: the mean (SD) MABP was
35.8 (3.8) mmHg in the albumin group and 34.4 (2.4) mmHg in
the control group. When the TPN was commenced on day three
the control group’s MABP was unchanged for the rest of the study
whereas the albumin group’s MABP continued to rise up until
day six when the mean (SD) MABP was 38.9 (4.8) mmHg. No
data are given for MABP on day six in the control group; however
it is stated that the difference in MABP between the two groups
was statistically significant (p < 0.05). Immediate adverse events of
albumin infusion including hypertension was one of our secondary
outcome measures: none of these data represent hypertension and
this reported difference is unlikely to have any clinical significance.
Other outcomes that were reported in this study that we did not
pre-specify include:
• Time taken to tolerate full feeds - albumin group mean (SD)
16.8 (7.6) days, and control group mean (SD) 18.8 (6.9) days
• Time taken to regain birth weight - albumin group mean (SD)
18.9 (5.9) days, and control group (SD) 24.9 (2.1) days
Greenough et al (Greenough 1993)
Primary outcome measures:
• Mortality and neurodevelopmental outcomes were not assessed
or reported
Secondary outcomes:
None of our secondary outcomes were reported.
The discussion section of the study report states that there were
no adverse effects with albumin in this study (none of the infants
required increased oxygen or ventilator support).
Other outcomes (that we did not pre-specify) were reported in
this study; these included:
• Fluid input versus output in 12 hour periods preceding infusion,
during infusion and post infusion. No significant differences
were reported.
• Albumin concentration pre and post infusion. The albumin
concentration increased significantly in the albumin group but
not in the placebo group.
• Weight pre and post infusion. Weight decreased significantly
in the albumin group and increased significantly in the placebo
group.
• Peak inspiratory pressures pre and post infusion. There was no
significant difference reported.
• Inspired oxygen concentration pre and post infusion. This did
fall significantly in the albumin group, and in the placebo group
it also fell but not significantly.
D I S C U S S I O N
The studies included in our review investigated a small, specific
subset of the total number of premature infants receiving albumin
infusions. Only one of the studies reported clinically relevant out-
comes (Kanarek 1992) - it found no significant differences for our
primary outcome measure of death or secondary outcome mea-
sures of IVH, PDA, NEC, bronchopulmonary dysplasia, duration
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of mechanical ventilation and duration of oxygen therapy. There
was a statistically significantly higher mean arterial BP in the albu-
min group at six days of age; however, this is unlikely to have any
clinical relevance. The results of this single small study should be
treated with caution - the confidence intervals for reported out-
comes are wide and a real difference might be masked by a type
2 error. Conversely, any differences seen could easily be due to
chance alone. Our second primary outcome (neurodevelopmental
outcome) and some of our secondary outcomes weren’t assessed in
the included studies (i.e. there were insufficient or no data to assess
other clinically important outcomes). The study by Greenough et
al (Greenough 1993) did not to report any of our primary and
secondary outcome measures.
In some neonatal intensive care units albumin is used frequently.
For example, at the Grantley Stable Neonatal Unit in Brisbane,
Australia, 12% of all preterm infants admitted and 38% of babies
<30 weeks GA will get at least one infusion of 20% albumin
to increase serum albumin levels or treat oedema [data from the
NeoData database, Royal Women’s Hospital, Brisbane for years
2000 to 2002 inclusive]. Such an extensive use of this treatment
should be based on better evidence than is currently available.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is a lack of evidence from randomised trials to determine
whether the routine use of albumin infusion, in preterm neonates
with low serum albumin, reduces mortality or morbidity, or is
associated with significant side effects.
Implications for research
If albumin infusion for hypoalbuminaemic pre-term infants is
thought to be worthwhile then there is a need for good quality,
double-blind randomised controlled trials to assess the safety and
efficacy of this practice.
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T A B L E S
Characteristics of included studies
Study Greenough 1993
Methods A RCT. The method of randomisation is unknown. Whether group allocation was blinded is unknown.
Whether the intervention was blinded is unknown. Data is analysed and reported for 30 of the 40 enrolled
participants. None of the outcomes reported are said to be blinded.
Participants Infants between 24 and 34 weeks gestation were eligible for the study if they were ventilator-dependant at
less than 7 days of age and had a serum albumin level of less than or equal to 30g/l. They were not eligible if
they were receiving peritoneal dialysis, had chest drains in situ or were hypotensive. Hypotension was defined
as a systolic blood pressure less than 40 mmHg.
40 infants were entered into the study. Data was incomplete for 5 in each group. The analysis was performed
on the remaining 30 participants (15 in each group).
Interventions 40 patients were randomly allocated to receive either albumin (n=20; 5 ml/kg 20% salt-poor human albumin)
or placebo (n=20; 5 ml/kg of infant’s maintenance fluids). The volume of the trial infusion was subtracted
from the total daily fluid requirement and given at the maintenance rate.
Outcomes Primary outcome measures: mortality and neurodevelopmental outcomes were not assessed or reported.
Secondary outcomes: none of our secondary outcomes were reported. The discussion section of the study
report states that there were no adverse effects with albumin in this study (none of the infants required
increased oxygen or ventilator support).
Other outcomes (that we did not pre-specify) reported:
Fluid input versus output in 12 hour periods preceding infusion, during infusion and post infusion.
Albumin concentration pre and post infusion.
Weight pre and post infusion.
Peak inspiratory pressures pre and post infusion.
Inspired oxygen concentration pre and post infusion.
Notes
Allocation concealment B
Study Kanarek 1992
Methods A RCT. The method of randomisation is unknown. Group allocation was blinded (sealed envelopes). The
intervention was blinded. Follow up was complete. It is unknown if outcome measurement was blinded.
Participants To be eligible the infants had to (1) have respiratory distress requiring assisted ventilation; (2) have had
significant hypotension (2 SD below the mean for gestational age, necessitating the use of a plasma expander
and/or inotropic agents); (3) have a plasma albumin level below 30 g/L at 48 to 72 hours of life and (4)
require TPN for nutritional support.
24 premature (not defined) infants were enrolled (12 in each group).
Interventions The albumin was added to the TPN in quantities that were calculated to raise the serum albumin above
30 g/L (maximum 1 g/kg/day). 24 patients were randomised to receive either added albumin to their TPN
(n=20) or standard TPN solution (n=20).
Outcomes Primary outcome measures:
Mortality.
Secondary outcomes:
intraventricular haemorrhages (not further defined).
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Characteristics of included studies (Continued )
Necrotising enterocolitis.
Bronchopulmonary dysplasia (not further defined).
Patent ductus arteriosus (not further defined).
The duration of assisted ventilation.
The duration of oxygen therapy.
The mean arterial blood pressures (MABP) were reported for days 3 and 6.
Other outcomes:
Time taken to tolerate full feeds.
Time taken to regain birth weight.
Notes
Allocation concealment A
Characteristics of excluded studies
Bland 1973 This RCT investigated albumin infusions in low birth weight newborn infants at risk for respiratory distress who were
acidaemic with a low total serum protein level (whether they were hypoalbuminaemic or not is unknown).
A N A L Y S E S
Comparison 01. Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation
(not defined)
Outcome title
No. of
studies
No. of
participants Statistical method Effect size
01 Mortality Relative Risk (Fixed) 95% CI Subtotals only
02 IVH - any grade Relative Risk (Fixed) 95% CI Subtotals only
03 Bronchopulmonary dysplasia
(not defined)
Relative Risk (Fixed) 95% CI Subtotals only
04 Necrotising enterocolitis Relative Risk (Fixed) 95% CI Subtotals only
05 Patent ductus arteriosus Relative Risk (Fixed) 95% CI Subtotals only
06 Duration of assisted ventilation
(days)
Weighted Mean Difference (Fixed) 95% CI Subtotals only
07 Duration of oxygen therapy
(days)
Weighted Mean Difference (Fixed) 95% CI Subtotals only
I N D E X T E R M S
Medical Subject Headings (MeSH)
Albumins [∗administration & dosage; adverse effects]; Hypoalbuminemia [mortality; ∗therapy]; Infant Mortality; Infant, Low Birth
Weight [blood]; Infant, Newborn; Infant, Premature [∗blood]
MeSH check words
Humans
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G R A P H S A N D O T H E R T A B L E S
Analysis 01.01. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 01 Mortality
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 01 Mortality
Study Albumin Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kanarek 1992 3/12 2/12 100.0 1.50 [ 0.30, 7.43 ]
Subtotal (95% CI) 12 12 100.0 1.50 [ 0.30, 7.43 ]
Total events: 3 (Albumin), 2 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.50 p=0.6
0.1 0.2 0.5 1 2 5 10
Favours albumin Favours control
Analysis 01.02. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 02 IVH - any grade
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 02 IVH - any grade
Study Albumin Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kanarek 1992 5/12 4/12 100.0 1.25 [ 0.44, 3.55 ]
Subtotal (95% CI) 12 12 100.0 1.25 [ 0.44, 3.55 ]
Total events: 5 (Albumin), 4 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.42 p=0.7
0.1 0.2 0.5 1 2 5 10
Favours albumin Favours control
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Analysis 01.03. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 03 Bronchopulmonary dysplasia (not defined)
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 03 Bronchopulmonary dysplasia (not defined)
Study Albumin Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kanarek 1992 5/12 6/12 100.0 0.83 [ 0.35, 2.00 ]
Subtotal (95% CI) 12 12 100.0 0.83 [ 0.35, 2.00 ]
Total events: 5 (Albumin), 6 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.41 p=0.7
0.1 0.2 0.5 1 2 5 10
Favours albumin Favours control
Analysis 01.04. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 04 Necrotising enterocolitis
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 04 Necrotising enterocolitis
Study Albumin Placebo Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kanarek 1992 0/12 1/12 100.0 0.33 [ 0.01, 7.45 ]
Subtotal (95% CI) 12 12 100.0 0.33 [ 0.01, 7.45 ]
Total events: 0 (Albumin), 1 (Placebo)
Test for heterogeneity: not applicable
Test for overall effect z=0.69 p=0.5
0.1 0.2 0.5 1 2 5 10
Favours albumin Favours control
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Analysis 01.05. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 05 Patent ductus arteriosus
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 05 Patent ductus arteriosus
Study Albumin No treatment Relative Risk (Fixed) Weight Relative Risk (Fixed)
n/N n/N 95% CI (%) 95% CI
Kanarek 1992 5/12 7/12 100.0 0.71 [ 0.31, 1.63 ]
Subtotal (95% CI) 12 12 100.0 0.71 [ 0.31, 1.63 ]
Total events: 5 (Albumin), 7 (No treatment)
Test for heterogeneity: not applicable
Test for overall effect z=0.80 p=0.4
0.1 0.2 0.5 1 2 5 10
Favours albumin Favours control
Analysis 01.06. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 06 Duration of assisted ventilation (days)
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 06 Duration of assisted ventilation (days)
Study Albumin Placebo Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Kanarek 1992 12 36.90 (22.90) 12 30.80 (15.20) 100.0 6.10 [ -9.45, 21.65 ]
Subtotal (95% CI) 12 12 100.0 6.10 [ -9.45, 21.65 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.77 p=0.4
-10.0 -5.0 0 5.0 10.0
Favours albumin Favours control
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Analysis 01.07. Comparison 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring
assisted ventilation (not defined), Outcome 07 Duration of oxygen therapy (days)
Review: Albumin infusion for low serum albumin in preterm newborn infants
Comparison: 01 Albumin vs placebo in infants with plasma albumin <30g/L and requiring assisted ventilation (not defined)
Outcome: 07 Duration of oxygen therapy (days)
Study Albumin Placebo Weighted Mean Difference (Fixed) Weight Weighted Mean Difference (Fixed)
N Mean(SD) N Mean(SD) 95% CI (%) 95% CI
Kanarek 1992 12 45.70 (19.10) 12 40.40 (12.50) 100.0 5.30 [ -7.62, 18.22 ]
Subtotal (95% CI) 12 12 100.0 5.30 [ -7.62, 18.22 ]
Test for heterogeneity: not applicable
Test for overall effect z=0.80 p=0.4
-10.0 -5.0 0 5.0 10.0
Favours albumin Favours control
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